We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Study to Examine Whether Rapid COVID-19 Antigen Tests Can Identify Infectious and Asymptomatic Individuals

By LabMedica International staff writers
Posted on 28 Oct 2020
Researchers are using rapid COVID-19 antigen tests in a study to examine their use among first responders and school-aged children, as well as understand whether these tests can identify infectious and asymptomatic individuals.

The study by researchers at the University of Southern California (Los Angeles, CA, USA) will examine the use of coronavirus rapid antigen tests among first responders and school-aged children. More...
The pilot study aims to determine the best methods for using the inexpensive tests with the hope of supporting reopening efforts. Rapid tests have the potential to quickly alert people who are contagious and need to isolate, thereby stopping the chain of transmission. Los Angeles is one of the first metropolitan areas in the country to launch a large-scale pilot study of rapid tests in both symptomatic and asymptomatic participants.

The first phase of the new project kicked off recently with firefighters at the Los Angeles Fire Department receiving three COVID-19 tests at city testing sites: a self-administered rapid antigen test, a lab-based PCR test and an antibody test to identify prior infection. The project, which aims to enroll up to 1,000 first responders, will provide insight into how each test performs and how to best administer these tests to essential frontline workers. The second phase of the project seeks to assess the feasibility, acceptability and accuracy of repeat rapid antigen testing for screening in school-aged children.

Researchers are looking at the pilot studies, focus groups and surveys as avenues to tackle a number of challenges, such as establishing the best way to deploy rapid testing, determining how often a person should repeat testing and identifying the best way to conduct large-scale testing and develop an effective implementation strategy.

“Rapid antigen tests have a lot of promise in our path to reopen schools and businesses because they are cheaper and provide quicker results than PCR tests. But there is a lot we don’t know,” said Neeraj Sood, director of the COVID Initiative at the USC Schaeffer Center for Health Policy & Economics and USC lead on the collaboration. “We want to understand whether rapid antigen tests identify infectious and asymptomatic individuals, whether they can be self-administered and how they can be used for screening at schools and workplaces. We are especially excited to be piloting a new rapid antigen test and mobile app that uses computer vision technology to automatically interpret results.”

Related Links:
University of Southern California


Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.